Opinion|Videos|July 10, 2024
EHA 2024 Insights: Impact of the IMROZ Study on Newly Diagnosed Multiple Myeloma
Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please discuss the data presented at the European Hematology Association 2024 (EHA 2024) Hybrid Congress on the IMROZ study of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) vs VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
- Please provide your key takeaways from this study. How do the results of this study impact the treatment of patients with transplant-ineligible NDMM?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
2
Fifth Death Confirmed in NYC Legionnaires' Outbreak
3
Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial
4
Contextualizing Golcadomide's Efficacy Signal in the RRFL Landscape
5